Contrasting VectivBio (NASDAQ:VECT) and iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of current recommendations for iTeos Therapeutics and VectivBio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	4	0	3.00
VectivBio	0	0	0	0	N/A

iTeos Therapeutics presently has a consensus target price of $30.50, indicating a potential upside of 255.06%. Given iTeos Therapeutics’ higher probable upside, research analysts clearly believe iTeos Therapeutics is more favorable than VectivBio.

Valuation and Earnings

This table compares iTeos Therapeutics and VectivBio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	$35.00 million	8.95	-$112.64 million	($3.78)	-2.27
VectivBio	$27.34 million	N/A	-$93.74 million	N/A	N/A

VectivBio has lower revenue, but higher earnings than iTeos Therapeutics.

Profitability

This table compares iTeos Therapeutics and VectivBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	-18.18%	-15.86%
VectivBio	N/A	N/A	N/A

Insider and Institutional Ownership

97.2% of iTeos Therapeutics shares are held by institutional investors. 12.5% of iTeos Therapeutics shares are held by company insiders. Comparatively, 9.7% of VectivBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

iTeos Therapeutics beats VectivBio on 5 of the 8 factors compared between the two stocks.

About iTeos Therapeutics

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.